CALL - SPRINTER OPEN END - MODERNA | Market Closed - Börse Stuttgart 15:50:18 2024-05-03 EDT | ||
| 8.61 EUR | -1.03% |
|
| Current month | +16.67% | ||
| 1 month | +34.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 8.61 | -1.03% | 0 |
| 24-05-02 | 8.7 | +17.89% | 0 |
| 24-04-30 | 7.38 | -0.27% | 0 |
| 24-04-29 | 7.4 | +4.67% | 0 |
| 24-04-26 | 7.07 | +3.06% | 0 |
Delayed Quote Börse Stuttgart
Last update May 03, 2024 at 03:50 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VP76A8 |
| ISIN | DE000VP76A88 |
| Date issued | 2020-09-09 |
| Strike | 33.01 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.68 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 40.23 € |
|---|---|
| Lowest since issue | 2.66 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
125
USD
Average target price
138.3
USD
Spread / Average Target
+10.65%
- Stock Market
- Certificates
- Certificat
